Literature DB >> 1417466

The treatment of agitation during initial hospitalization after traumatic brain injury.

M M Brooke1, D R Patterson, K A Questad, D Cardenas, L Farrel-Roberts.   

Abstract

Agitation after traumatic brain injury is disruptive for patient care, distressing, and difficult to treat. The use of propranolol has been advocated to control agitation after brain injury. It reportedly lacks some of the deleterious cognitive and emotional effects of other medications and physical restraints. This study was designed to test if propranolol is effective in reducing agitated behavior. Subjects had traumatic closed-head injury treated at a combined Level I Trauma Center and Rehabilitation Center. Twenty-one subjects met the criteria of agitation and were treated with propranolol or placebo in a double-blind fashion. The intensity of agitation was significantly lower in the treatment group although the number of episodes were similar. The use of restraints was also significantly lower in the treatment group. The results support the effectiveness of propranolol in reducing the intensity of agitation during the initial hospitalization after closed-head injury.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1417466

Source DB:  PubMed          Journal:  Arch Phys Med Rehabil        ISSN: 0003-9993            Impact factor:   3.966


  17 in total

1.  Successfully treating aggression in mentally ill prison inmates.

Authors:  C F Lewis
Journal:  Psychiatr Q       Date:  2000

Review 2.  Neuropsychiatry of aggression.

Authors:  Scott D Lane; Kimberly L Kjome; F Gerard Moeller
Journal:  Neurol Clin       Date:  2011-02       Impact factor: 3.806

3.  Spontaneous recovery after controlled cortical impact injury is not impeded by intermittent administration of the antipsychotic drug risperidone.

Authors:  Lauren J Carlson; Gina C Bao; Sonya Besagar; Jacob B Leary; Hannah L Radabaugh; Corina O Bondi; Anthony E Kline
Journal:  Neurosci Lett       Date:  2018-06-06       Impact factor: 3.046

4.  Reliability and validity of the Overt Agitation Severity Scale in adult psychiatric inpatients.

Authors:  H J Kopecky; C R Kopecky; S C Yudofsky
Journal:  Psychiatr Q       Date:  1998

Review 5.  Elucidating opportunities and pitfalls in the treatment of experimental traumatic brain injury to optimize and facilitate clinical translation.

Authors:  Patricia B de la Tremblaye; Darik A O'Neil; Megan J LaPorte; Jeffrey P Cheng; Joshua A Beitchman; Theresa Currier Thomas; Corina O Bondi; Anthony E Kline
Journal:  Neurosci Biobehav Rev       Date:  2017-05-30       Impact factor: 8.989

Review 6.  Common psychiatric syndromes and pharmacologic treatments of traumatic brain injury.

Authors:  L A Labbate; D L Warden
Journal:  Curr Psychiatry Rep       Date:  2000-06       Impact factor: 5.285

Review 7.  Acquired Brain Injury in the Pediatric Intensive Care Unit: Special Considerations for Delirium Protocols.

Authors:  Ana Ubeda Tikkanen; Sapna R Kudchadkar; Sarah W Goldberg; Stacy J Suskauer
Journal:  J Pediatr Intensive Care       Date:  2020-11-03

8.  Intermittent Administration of Haloperidol after Cortical Impact Injury Neither Impedes Spontaneous Recovery Nor Attenuates the Efficacy of Environmental Enrichment.

Authors:  Gina C Bao; Isabel H Bleimeister; Lydia A Zimmerman; JoDy L Wellcome; Peter J Niesman; Hannah L Radabaugh; Corina O Bondi; Anthony E Kline
Journal:  J Neurotrauma       Date:  2019-01-09       Impact factor: 5.269

9.  Relative to Typical Antipsychotic Drugs, Aripiprazole Is a Safer Alternative for Alleviating Behavioral Disturbances After Experimental Brain Trauma.

Authors:  Thomas I Phelps; Corina O Bondi; Vincent V Mattiola; Anthony E Kline
Journal:  Neurorehabil Neural Repair       Date:  2016-05-24       Impact factor: 3.919

10.  Decreasing adrenergic or sympathetic hyperactivity after severe traumatic brain injury using propranolol and clonidine (DASH After TBI Study): study protocol for a randomized controlled trial.

Authors:  Mayur B Patel; John W McKenna; JoAnn M Alvarez; Ayaka Sugiura; Judith M Jenkins; Oscar D Guillamondegui; Pratik P Pandharipande
Journal:  Trials       Date:  2012-09-26       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.